5-(4-异丙苯基)-5-氧戊酸 | 898791-85-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-(4-异丙苯基)-5-氧戊酸
• 英文名称: 5-Oxo-5-(4-isopropoxyphenyl)valeric acid
• 英文别名: 5-oxo-5-(4-propan-2-yloxyphenyl)pentanoic acid
• CAS: 898791-85-0
• 化学式: C₁₄H₁₈O₄
• mdl: MFCD02260992
• 分子量: 250.29
• InChiKey: SQGMMNSIZRTKOW-UHFFFAOYSA-N

物化性质

• 沸点：
  437.5±25.0 °C(Predicted)
• 密度：
  1.124±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090

文献信息

• 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：Siegel Craig

  公开号：US20100256216A1

  公开（公告）日：2010-10-07

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式（I）表示，或其药学上可接受的盐。一种药物组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。一种治疗需要的受试者的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。该受试者患有2型糖尿病；与糖尿病性肾病相关的肾肥大或增生；Tay-Sachs病；高氏病；或Fabry病。分别降低受试者血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡糖鞘氨醇合成酶和降低糖脂浓度的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。
• GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE
  申请人：Genzyme Corporation

  公开号：US20130225573A1

  公开（公告）日：2013-08-29

  A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

  一种治疗肾小球疾病的方法，所述肾小球疾病选自系列包括系膜增生性肾小球肾炎、崩解性肾小球病、增生性狼疮性肾炎、新月体性肾小球肾炎和膜性肾病，该方法包括向受试者施用有效量的葡糖鞘氨醇合成酶抑制剂。
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20150225393A1

  公开（公告）日：2015-08-13

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式(I)表示，或其药学上可接受的盐。一种制药组合物包括一种由结构式(I)表示的化合物或其药学上可接受的盐。一种治疗需要的受体的方法包括向受体施用由结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。该受体患有2型糖尿病；与糖尿病性肾病相关的肾肥大或增生；Tay-Sachs病；Gaucher病；或Fabry病。分别降低患者血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡萄糖酰胺合成酶和降低糖脂质浓度的方法包括向需要的受体施用由结构式(I)表示的化合物或其药学上可接受的盐的治疗有效量。
• Ceramide derivatives for treating polycystic kidney disease
  申请人：GENZYME CORPORATION

  公开号：EP2550965A2

  公开（公告）日：2013-01-30

  A compound represented by Structural Formula (1) or a pharmaceutically acceptable salt thereof for use in treating polycystic kidney disease.

  一种由结构式（1）代表的化合物或其药学上可接受的盐，用于治疗多囊肾病。
• 2-acylaminopropanol-type glucosylceramide synthase inhibitors
  申请人：Genzyme Corporation

  公开号：EP2594562A2

  公开（公告）日：2013-05-22

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentration in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式 (I) 代表：或其药学上可接受的盐。一种药物组合物包含由结构式（I）代表的化合物或其药学上可接受的盐。一种治疗有需要的受试者的方法，包括向受试者施用治疗有效量的结构式（I）所代表的化合物或其药学上可接受的盐。受试者患有 2 型糖尿病；与糖尿病肾病相关的肾肥大或增生；Tay-Sachs；Gaucher 或 Fabry 病。降低血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡萄糖酰甘油酰胺合成酶和降低糖磷脂浓度的方法包括向有需要的受试者分别施用治疗有效量的由结构式(I)代表的化合物或其药学上可接受的盐。